The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly

Clinical Infectious Diseases

Volumn 61, Issue 12, 2015, Pages 1835-1838

  Van Werkhoven, Cornelis H ^a   Huijts, Susanne M ^a,b   Bolkenbaas, Marieke ^a   Grobbee, Diederick E ^a   Bonten, Marc J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Department of Pulmonary Medicine ^*  (United States)

Author keywords

communityacquired pneumonia; immunosenescence; invasive pneumococcal disease; pneumococcal conjugate vaccine; vaccine efficacy

Indexed keywords

PLACEBO; PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE;

AGE; AGED; ARTICLE; BLOOD CULTURE; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; HUMAN; NONHUMAN; PNEUMOCOCCAL INFECTION; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROTYPE; VACCINATION; VERY ELDERLY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; IMMUNOLOGY; MALE; PNEUMOCOCCAL INFECTIONS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; TREATMENT OUTCOME;

EID: 84959249701     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ686     Document Type: Article

References (13)

1. Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. Age effects on B cells and humoral immunity in humans. Aging Res Rev 2011; 10:330-5.
2. Siegrist C-A, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009; 9:185-94.
3. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 2012; 24:331-41.
4. Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transpl Int 2009; 22:1041-50.
5. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999; 29:281-8.
6. De Roux A, Schmöle-Thoma B, Schmöele-Thoma B, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46:1015-23.
7. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577-84.
8. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114-25..
9. Huijts SM, Pride MW, Vos JM, et al. Diagnostic accuracy of a serotypespecific antigen test in community-acquired pneumonia. Eur Respir J 2013; 42:1283-90.
10. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria, 2013. Available at: http://www.r-project.org/. Accessed 25 August 2015.
11. Macintyre CR, Ridda I, Gao Z, et al. A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly. PLoS One 2014; 9:e94578.
12. Dbaibo G, El-Ayoubi N, Ghanem S, et al. Immunogenicity and safety of a quadrivalentmeningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial. Drugs Aging 2013; 30:309-19.
13. Vermeiren AP, Hoebe CJ, Dukers-Muijrers NH. High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. J Clin Virol 2013; 58:262-4.